logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

JF SMARTINVEST (09636) repurchased approximately 70,500 shares for about HKD 2.3196 million on April 29th.

date
19:05 29/04/2026
avatar
GMT Eight
Nine Profit Intelligent Investment Holdings Limited (09636) announced that on April 29, 2026, it spent approximately HK$2.3196 million to repurchase 70,500 shares.
JF SMARTINVEST (09636) announced a buyback of approximately 231.96 million Hong Kong dollars to repurchase 70,500 shares on April 29, 2026.
Related Articles
HK Stock
Midea Group Co., Ltd (00300) had a first quarter attributable net profit of 12.675 billion yuan, an increase of 2.03% year-on-year.
HK Stock
MICROPORT NEURO (02172) spent approximately HK$1.0348 million to repurchase 100,000 shares on April 29th.
HK Stock
Hansoh Pharma (03692): B7-H3 targeted antibody-drug conjugate HS-20093 approved as breakthrough therapy for castration-resistant prostate cancer.
Midea Group Co., Ltd (00300) had a first quarter attributable net profit of 12.675 billion yuan, an increase of 2.03% year-on-year.
HK Stock
MICROPORT NEURO (02172) spent approximately HK$1.0348 million to repurchase 100,000 shares on April 29th.
HK Stock
Hansoh Pharma (03692): B7-H3 targeted antibody-drug conjugate HS-20093 approved as breakthrough therapy for castration-resistant prostate cancer.
HK Stock
RECOMMEND
China Leads as Humanoid Robotics Reach Commercial Turning Point
China Leads as Humanoid Robotics Reach Commercial Turning Point
icon
29/04/2026
AI Disruption Reshapes US Equity Valuations as Terminal Value Volatility Takes Center Stage
AI Disruption Reshapes US Equity Valuations as Terminal Value Volatility Takes Center Stage
icon
29/04/2026
Political Bureau Meeting Sets Tone for Growth Eight Key Takeaways on Property Capital Markets and Monetary Policy
Political Bureau Meeting Sets Tone for Growth Eight Key Takeaways on Property Capital Markets and Monetary Policy
icon
29/04/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.